These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 25772512

  • 1. Comprehensive geriatric assessment and traditional Chinese medicine intervention benefit symptom control in elderly patients with advanced non-small cell lung cancer.
    Xue D, Han S, Jiang S, Sun H, Chen Y, Li Y, Wang W, Feng Y, Wang K, Li P.
    Med Oncol; 2015 Apr; 32(4):114. PubMed ID: 25772512
    [Abstract] [Full Text] [Related]

  • 2. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
    Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M, Yang JC.
    J Thorac Oncol; 2013 Feb; 8(2):229-37. PubMed ID: 23328549
    [Abstract] [Full Text] [Related]

  • 3. [Prognostic analysis of stage III-IV non-small cell lung cancer patients treated by traditional chinese medicine].
    Zhou DH, Lin LZ, Zhou YQ, Luo RC, Liu KF, Jia YJ, Chen JY, Niu XW, Su BR, Lu J, Wang ST.
    Ai Zheng; 2005 Oct; 24(10):1252-6. PubMed ID: 16219143
    [Abstract] [Full Text] [Related]

  • 4. Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non-small-Cell Lung Cancer.
    Dawe DE, Pond GR, Ellis PM.
    Clin Lung Cancer; 2016 Nov; 17(6):563-572.e2. PubMed ID: 27374398
    [Abstract] [Full Text] [Related]

  • 5. Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial.
    Jiang Y, Liu LS, Shen LP, Han ZF, Jian H, Liu JX, Xu L, Li HG, Tian JH, Mao ZJ.
    Complement Ther Med; 2016 Feb; 24():55-62. PubMed ID: 26860802
    [Abstract] [Full Text] [Related]

  • 6. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer.
    Brown J, Thorpe H, Napp V, Fairlamb DJ, Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG, Stephens RJ, Waller D, West P, Peake MD.
    J Clin Oncol; 2005 Oct 20; 23(30):7417-27. PubMed ID: 16157935
    [Abstract] [Full Text] [Related]

  • 7. [A multicenter, large-sample, randomized clinical trial on improving the median survival time of advanced non-small cell lung cancer by combination of Ginseng Rg3 and chemotherapy].
    Zhang Y, Wang XQ, Liu H, Liu J, Hou W, Lin HS.
    Zhonghua Zhong Liu Za Zhi; 2018 Apr 23; 40(4):295-299. PubMed ID: 29730918
    [Abstract] [Full Text] [Related]

  • 8. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
    Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G, Surmont V, Li Q, Deitz AC, Lubiniecki GM, Herbst RS.
    J Thorac Oncol; 2019 May 23; 14(5):793-801. PubMed ID: 30711649
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
    Mu XL, Li LY, Zhang XT, Wang SL, Wang MZ.
    BMC Cancer; 2004 Aug 19; 4():51. PubMed ID: 15318946
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.
    Lancet Oncol; 2012 Mar 19; 13(3):247-55. PubMed ID: 22341744
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older.
    Chen YM, Tsai CM, Fan WC, Shih JF, Liu SH, Wu CH, Chou TY, Lee YC, Perng RP, Whang-Peng J.
    J Thorac Oncol; 2012 Feb 19; 7(2):412-8. PubMed ID: 22157367
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer.
    Tatli AM, Arslan D, Uysal M, Goksu SS, Gunduz SG, Coskun HS, Ozdogan M, Savas B, Bozcuk HS.
    J Cancer Res Ther; 2015 Feb 19; 11(4):805-9. PubMed ID: 26881522
    [Abstract] [Full Text] [Related]

  • 20. Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated non-small-cell lung cancer.
    Takatani H, Nakamura Y, Nagashima S, Soda H, Kinoshita A, Fukuda M, Fukuda M, Soejima Y, Kasai T, Nakatomi K, Iida T, Oka M, Tsukamoto K, Kohno S.
    Clin Lung Cancer; 2012 Sep 19; 13(5):347-51. PubMed ID: 22264660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.